Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 2Neoplasms 2Fallopian Tube Neoplasms 2Radiation Pneumonitis 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 162Radiosurgery 115Radiotherapy 100Bevacizumab 96Magnetic Resonance Spectroscopy 65Carboplatin 48Etoposide 34pembrolizumab 33Surgical Procedures, Operative 33Irinotecan 33Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 30Carmustine 28Lomustine 25Cisplatin 25Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × Angiogenesis Inhibitors × Clear all
NCT03890952 2025-07-24

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Rigshospitalet, Denmark

Phase 2 Completed
40 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡